3D model (JSmol)
|Molar mass||450.79 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Cetyl myristoleate is a chemical compound which is a type of fatty acid ester or, more specifically, a cetylated fatty acid (CFA). It is the cetyl ester of myristoleic acid. Although it is used as a dietary supplement, there is little clinical evidence to support a benefit for any medical condition.
In animal studies, cetyl myristoleate was first reported to block inflammation and prevent adjuvant-induced arthritis at very high doses in rats. Other studies using identical and similar methods have failed to replicate this effect. In follow-up studies in mice, a modest anti-inflammatory effect was observed.
Study in humans
Although cetyl myristoleate is sold as a dietary supplement, its possible benefits in the treatment of any medical condition are largely unknown and the Federal Trade Commission has taken legal action against supplement manufacturers for exaggerated claims.
There is some clinical evidence for the benefits of CFAs, which may contain cetyl myristoleate, in arthritic patients. One pilot study found that cetyl myristoleate may be beneficial against fibromyalgia. However, these low-quality clinical trials provide only limited scientific evidence of efficacy.
- Ameye, Laurent G; Chee, Winnie SS (2006). "From nutraceuticals to functional foods". Arthritis Research & Therapy. 8 (4): R127. PMC . PMID 16859534. doi:10.1186/ar2016.
- Hunter, Kenneth W; Gault, Ruth A; Stehouwer, Jeffrey S; Tam-Chang, Suk-Wah (2003). "Synthesis of cetyl myristoleate and evaluation of its therapeutic efficacy in a murine model of collagen-induced arthritis". Pharmacological Research. 47 (1): 43–7. PMID 12526860. doi:10.1016/S1043-6618(02)00239-6.
- H.W Diehl, E.L May (1994). "Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats". J Pharm Sci. 83 (3): 296–9. PMID 8207671. doi:10.1002/jps.2600830307.
- Whitehouse, MW; McGeary, RP (1999). "Concerning the anti-arthritic action of cetyl myristoleate in rats: An interim report". Inflammopharmacology. 7 (3): 303–10. PMID 17638102. doi:10.1007/s10787-999-0014-z.
- See for example:
• DOCKET NO. C-3896 Archived April 21, 2013, at the Wayback Machine., Federal Trade Commission
• FTC Complaint against EHP Products, Inc.
• FTP Complaint against CMO Distribution Centers of America, Inc.
- Hesslink Jr, R; Armstrong d, 3rd; Nagendran, MV; Sreevatsan, S; Barathur, R (2002). "Cetylated fatty acids improve knee function in patients with osteoarthritis". The Journal of rheumatology. 29 (8): 1708–12. PMID 12180734.
- A.M Edwards (2001). "CMO (cerasomol-cis-9-cetyl myristoleate) in the treatment of fibromyalgia: an open pilot study". J. Nutr. Environ. Med. 11 (2): 105–111. doi:10.1080/13590840120060849.